DK1951674T3 - Sulfonamidderivater og anvendelse deraf til modulation af metalloproteinaser - Google Patents
Sulfonamidderivater og anvendelse deraf til modulation af metalloproteinaserInfo
- Publication number
- DK1951674T3 DK1951674T3 DK06807508.4T DK06807508T DK1951674T3 DK 1951674 T3 DK1951674 T3 DK 1951674T3 DK 06807508 T DK06807508 T DK 06807508T DK 1951674 T3 DK1951674 T3 DK 1951674T3
- Authority
- DK
- Denmark
- Prior art keywords
- sulfonamide derivatives
- diseases
- metalloproteinases
- modulation
- fibrosis
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/44—Iso-indoles; Hydrogenated iso-indoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/4035—Isoindoles, e.g. phthalimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
- C07D217/08—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with a hetero atom directly attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US73040405P | 2005-10-26 | 2005-10-26 | |
EP05110035 | 2005-10-26 | ||
PCT/EP2006/067713 WO2007048788A1 (en) | 2005-10-26 | 2006-10-24 | Sulfonamide derivatives and use thereof for the modulation of metalloproteinases |
Publications (1)
Publication Number | Publication Date |
---|---|
DK1951674T3 true DK1951674T3 (da) | 2012-01-02 |
Family
ID=35695473
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK06807508.4T DK1951674T3 (da) | 2005-10-26 | 2006-10-24 | Sulfonamidderivater og anvendelse deraf til modulation af metalloproteinaser |
Country Status (22)
Country | Link |
---|---|
US (1) | US7879876B2 (da) |
EP (1) | EP1951674B1 (da) |
JP (1) | JP5203956B2 (da) |
KR (1) | KR20080064880A (da) |
CN (1) | CN101346353B (da) |
AT (1) | ATE534630T1 (da) |
AU (1) | AU2006307939B2 (da) |
BR (1) | BRPI0617931A2 (da) |
CA (1) | CA2623879C (da) |
CY (1) | CY1112370T1 (da) |
DK (1) | DK1951674T3 (da) |
EA (1) | EA013907B1 (da) |
ES (1) | ES2372866T3 (da) |
HK (1) | HK1123304A1 (da) |
HR (1) | HRP20110874T1 (da) |
IL (1) | IL190835A (da) |
PL (1) | PL1951674T3 (da) |
PT (1) | PT1951674E (da) |
RS (1) | RS52229B (da) |
SI (1) | SI1951674T1 (da) |
WO (1) | WO2007048788A1 (da) |
ZA (1) | ZA200803327B (da) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2007000428A (es) | 2004-07-15 | 2008-03-05 | Amr Technology Inc | Tetrahidroisoquinolinas sustituidas con arilo y heteroarilo y uso de las mismas para bloquear la captacion de norepinefrina, dopamina y serotonina. |
US9156812B2 (en) | 2008-06-04 | 2015-10-13 | Bristol-Myers Squibb Company | Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine |
BRPI0921826A2 (pt) * | 2008-11-11 | 2016-01-12 | Novartis Ag | compostos orgânicos |
EP2429293B1 (en) | 2009-05-12 | 2014-10-29 | Bristol-Myers Squibb Company | CRYSTALLINE FORMS OF (S)-7-([1,2,4]TRIAZOLO[1,5-a]PYRIDIN-6-YL)-4-(3,4-DICHLOROHPHENYL)-1,2,3,4-TETRAHYDROISOQUINOLINE AND USE THEREOF |
ES2662072T3 (es) | 2009-05-12 | 2018-04-05 | Albany Molecular Research, Inc. | 7-([1,2,4]triazolo[1,5-a]piridin-6-il)-4-(3,4-diclorofenil)-1,2,3,4-tetrahidroisoquinolina y uso de la misma |
KR20120034644A (ko) | 2009-05-12 | 2012-04-12 | 알바니 몰레큘라 리써치, 인크. | 아릴, 헤테로아릴, 및 헤테로사이클 치환된 테트라하이드로이소퀴놀린 및 이의 용도 |
HUE026406T2 (en) * | 2009-06-19 | 2016-06-28 | Teva Pharma | Treatment of multiple sclerosis with laquinimod |
PL2458992T3 (pl) * | 2009-07-30 | 2016-07-29 | Teva Pharma | Leczenie choroby Leśniowskiego-Crohna z użyciem lakwinimodu |
ME02495B (me) | 2009-08-10 | 2017-02-20 | Teva Pharma | Tretman poremećaja koji su u vezi sa bdnf primenom lakvinimoda |
WO2013073667A1 (ja) * | 2011-11-18 | 2013-05-23 | 日東電工株式会社 | 腸管線維症処置剤 |
AU2011223697B2 (en) * | 2010-03-03 | 2016-07-14 | Teva Pharmaceutical Industries Ltd. | Treatment of rheumatoid arthritis with a combination of laquinimod and methotrexate |
PL2542080T3 (pl) * | 2010-03-03 | 2017-02-28 | Teva Pharmaceutical Industries Ltd. | Leczenie toczniowego zapalenia stawów z zastosowaniem lakwinimodu |
SG183512A1 (en) * | 2010-03-03 | 2012-09-27 | Teva Pharma | Treatment of lupus nephritis using laquinimod |
JP5950428B2 (ja) * | 2010-08-05 | 2016-07-13 | 日東電工株式会社 | 線維化組織から正常組織を再生するための組成物 |
SG188545A1 (en) * | 2010-09-17 | 2013-04-30 | Univ Tokyo | Composition for maintaining function of platelets |
US8889627B2 (en) | 2011-10-12 | 2014-11-18 | Teva Pharmaceutical Industries, Ltd. | Treatment of multiple sclerosis with combination of laquinimod and fingolimod |
AR089862A1 (es) | 2012-02-03 | 2014-09-24 | Teva Pharma | USO DE LAQUINIMOD PARA EL TRATAMIENTO DE PACIENTES CON ENFERMEDAD DE CROHN EN QUIENES FRACASO UNA TERAPIA ANTI-FACTOR DE NECROSIS TUMORAL a (ANTI-TNFa) DE PRIMERA LINEA |
TW201400117A (zh) | 2012-06-05 | 2014-01-01 | Teva Pharma | 使用拉喹莫德治療眼發炎疾病 |
CN103102304B (zh) * | 2013-01-19 | 2015-03-11 | 安徽师范大学 | N-磺酰基取代四氢异喹啉衍生物的制备方法 |
WO2023147063A2 (en) * | 2022-01-28 | 2023-08-03 | Opna Bio SA | Compounds and methods for yap/tead modulation and indications therefor |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9919776D0 (en) * | 1998-08-31 | 1999-10-27 | Zeneca Ltd | Compoujnds |
EP1187811B1 (en) * | 1999-06-04 | 2007-03-07 | AstraZeneca AB | Inhibitors of metalloproteinases |
US6506773B2 (en) * | 2000-05-15 | 2003-01-14 | Darwin Discovery Ltd. | Hydroxamic and carboxylic acid derivatives |
GB0216383D0 (en) * | 2002-07-13 | 2002-08-21 | Astrazeneca Ab | Compounds |
SE0301922D0 (sv) * | 2003-06-27 | 2003-06-27 | Astrazeneca Ab | Novel compounds |
-
2006
- 2006-10-24 US US12/091,582 patent/US7879876B2/en not_active Expired - Fee Related
- 2006-10-24 EA EA200801183A patent/EA013907B1/ru not_active IP Right Cessation
- 2006-10-24 SI SI200631208T patent/SI1951674T1/sl unknown
- 2006-10-24 ES ES06807508T patent/ES2372866T3/es active Active
- 2006-10-24 RS RS20120059A patent/RS52229B/en unknown
- 2006-10-24 ZA ZA200803327A patent/ZA200803327B/xx unknown
- 2006-10-24 WO PCT/EP2006/067713 patent/WO2007048788A1/en active Application Filing
- 2006-10-24 DK DK06807508.4T patent/DK1951674T3/da active
- 2006-10-24 KR KR1020087012135A patent/KR20080064880A/ko not_active Application Discontinuation
- 2006-10-24 PL PL06807508T patent/PL1951674T3/pl unknown
- 2006-10-24 BR BRPI0617931-2A patent/BRPI0617931A2/pt not_active IP Right Cessation
- 2006-10-24 EP EP06807508A patent/EP1951674B1/en active Active
- 2006-10-24 CA CA2623879A patent/CA2623879C/en not_active Expired - Fee Related
- 2006-10-24 AT AT06807508T patent/ATE534630T1/de active
- 2006-10-24 CN CN2006800490790A patent/CN101346353B/zh not_active Expired - Fee Related
- 2006-10-24 JP JP2008537083A patent/JP5203956B2/ja not_active Expired - Fee Related
- 2006-10-24 PT PT06807508T patent/PT1951674E/pt unknown
- 2006-10-24 AU AU2006307939A patent/AU2006307939B2/en not_active Ceased
-
2008
- 2008-04-14 IL IL190835A patent/IL190835A/en not_active IP Right Cessation
-
2009
- 2009-04-06 HK HK09103218.1A patent/HK1123304A1/xx not_active IP Right Cessation
-
2011
- 2011-11-23 HR HR20110874T patent/HRP20110874T1/hr unknown
-
2012
- 2012-02-17 CY CY20121100170T patent/CY1112370T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
EP1951674B1 (en) | 2011-11-23 |
EA200801183A1 (ru) | 2008-10-30 |
EA013907B1 (ru) | 2010-08-30 |
US7879876B2 (en) | 2011-02-01 |
AU2006307939A1 (en) | 2007-05-03 |
ZA200803327B (en) | 2009-09-30 |
HRP20110874T1 (hr) | 2011-12-31 |
IL190835A (en) | 2013-01-31 |
US20090221575A1 (en) | 2009-09-03 |
ATE534630T1 (de) | 2011-12-15 |
IL190835A0 (en) | 2008-11-03 |
CN101346353A (zh) | 2009-01-14 |
ES2372866T3 (es) | 2012-01-27 |
BRPI0617931A2 (pt) | 2011-08-09 |
SI1951674T1 (sl) | 2012-01-31 |
CN101346353B (zh) | 2012-01-11 |
HK1123304A1 (en) | 2009-06-12 |
CY1112370T1 (el) | 2015-12-09 |
PL1951674T3 (pl) | 2012-04-30 |
RS52229B (en) | 2012-10-31 |
JP2009513601A (ja) | 2009-04-02 |
CA2623879C (en) | 2014-03-25 |
KR20080064880A (ko) | 2008-07-09 |
WO2007048788A1 (en) | 2007-05-03 |
CA2623879A1 (en) | 2007-05-03 |
AU2006307939B2 (en) | 2012-03-29 |
PT1951674E (pt) | 2011-12-19 |
JP5203956B2 (ja) | 2013-06-05 |
EP1951674A1 (en) | 2008-08-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK1951674T3 (da) | Sulfonamidderivater og anvendelse deraf til modulation af metalloproteinaser | |
NO20070994L (no) | N-hydroksamid derivater og anvendelse derav | |
EA200601868A1 (ru) | 3- или 4-монозамещённые производные фенола и тиофенола, полезные в качестве н-лигандов | |
EA200601141A1 (ru) | Сульфонамидные производные для лечения заболеваний | |
EA201291273A1 (ru) | Ингибиторы киназ, регулирующих апоптозный сигнал | |
EA201001129A1 (ru) | Пиримидины в качестве ингибиторов киназы | |
EA201001127A1 (ru) | Производные пиридина | |
DK1828160T3 (da) | Cykliske sulfonylaminoderivater og anvendelse deraf som MMP-hæmmere | |
WO2010042649A3 (en) | PHTHALAZINE COMPOUNDS AS p38 MAP KINASE MODULATORS AND METHODS OF USE THEREOF | |
DK1844032T3 (da) | N-hydroxyamid-derivater og deres anvendelse | |
CY1112088T1 (el) | Παραγωγα ν-υδροξυαμιδης και η χρηση τους | |
NO20070820L (no) | Oktahydropyrrolo (2,3,C)pyridin-derivanter og farmasoytisk anvendelse derav. | |
UA88785C2 (en) | N-hydroxyamide derivatives and use thereof | |
CY1112367T1 (el) | Κυκλικα παραγωγα σουλφονυλ αμινο και χρηση αυτων ως μμρ αναστολεων |